Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6206951 | 0.90 | EPHX1 (0.49) | EPHX1CYP1A2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL528414 | 0.89 | EPHX1 (0.56) | EPHX1ALOX5LMNAHSD17B10MMP9 | |
| SCHEMBL1945087 | 0.87 | EPHX1 (0.54) | EPHX1ALOX5LMNAHSD17B10MMP9 | |
| Hydrochloric Acid SCHEMBL31092601 | 0.87 | EPHX1 (0.54) | EPHX1ALOX5LMNAHSD17B10MMP9 | |
| SCHEMBL18248508 | 0.86 | EPHX1 (0.53) | EPHX1LMNAMMP9MMP8MMP13 | |
| SCHEMBL1404164 | 0.86 | EPHX1 (0.53) | EPHX1LMNAMMP9MMP8MMP13 | |
| SCHEMBL8763769 | 0.86 | EPHX1 (0.53) | EPHX1LMNAMMP9MMP8MMP13 | |
| SCHEMBL21359023 | 0.86 | EPHX1 (0.53) | EPHX1LMNAMMP9MMP8MMP13 | |
| SCHEMBL4555669 | 0.86 | EPHX1 (0.53) | EPHX1LMNAMMP9MMP8MMP13 | |
| SCHEMBL7642789 | 0.86 | EPHX1 (0.53) | EPHX1LMNAMMP9MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190680-A1 | Heteroaryl Amide Analogues | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | claimed |
| EP-2185560-A1 | HETEROARYL AMIDE ANALOGUES | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | claimed |
| WO-2009108551-A2 | HETEROARYL AMIDE ANALOGUES | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | claimed |
| WO-2009023623-A1 | HETEROARYL AMIDE ANALOGUES | H, LUNDBECK A/S (DK) | 2009-02-19 | — | — | WO | claimed |
| EP-1888525-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-02-20 | — | — | EP | claimed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | claimed |
| WO-2006117754-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | claimed |
| CN-1791407-A | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists | PFIZER (US) | 2006-06-21 | — | — | CN | claimed |
| WO-2005007094-A2 | ASTHMA AND ALLERGIC INFLAMMATION MODULATORS | TULARIK INC. (US) | 2005-01-27 | — | — | WO | claimed |
| US-12459921-B2 | Isoindoline compound, preparation method, pharmaceutical composition and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-11-04 | — | — | US | disclosed |
| US-RE49594-E1 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2023-08-01 | — | — | US | disclosed |
| EP-4192824-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | Cornell University (US) | 2023-06-14 | — | — | EP | disclosed |
| US-11535630-B2 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2022-12-27 | — | — | US | disclosed |
| CN-113214104-B | Method for synthesizing aromatic acetamide | 浙江工业大学 | 2022-05-24 | — | — | CN | disclosed |
| EP-0833637-A4 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONIST | MERCK & CO INC (US) | 1998-07-08 | — | — | EP | disclosed |
| EP-0833637-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONIST | Merck & Co., Inc. (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996040136-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| CN-1122331-A | Benzene, pyridine and pyrimidine derivative | EISAI CO LTD (JP) | 1996-05-15 | — | — | CN | disclosed |
| EP-0706994-A1 | Melatonergic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-04-17 | — | — | EP | disclosed |
| CN-1060466-A | Derivatives of Benzene, Pyridine and Pyrimidine | EISAI CO LTD (JP) | 1992-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | EPHX1 3506/4885CYP1A2 3207/4885CYP2D6 2043/4885 |
| US-11535630-B2 | Apelin receptor (APJ) agonists and uses thereof | APLNR, AP1G1, APMAP | EPHX1 3387/4885CYP1A2 4586/4885CYP2D6 4712/4885 |
| US-12459921-B2 | Isoindoline compound, preparation method, pharmaceutical composition and use thereof | CUL4B, CUL4A, UBQLN1 | EPHX1 2669/4885CYP1A2 379/4885CYP2D6 645/4885 |
| US-20120190680-A1 | Heteroaryl Amide Analogues | P2RX3, P2RX2, ADORA2A | EPHX1 827/4885CYP1A2 787/4885CYP2D6 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.